Core Viewpoint - ST Tian Sheng (002872) announced that it and its wholly-owned subsidiary Hubei Tian Sheng Pharmaceutical participated in the national organized procurement of drugs, with three products included in the proposed selection list [1] Group 1: Selected Products - The selected products include Paracetamol Tablets, Lidocaine Hydrochloride Injection, and Furosemide Injection, which are commonly used in clinical settings for treating symptoms such as fever, pain relief, local anesthesia, arrhythmias, and edema-related diseases [1] - The final selection results will be confirmed by the procurement office's official announcement [1] Group 2: Market Impact - The company stated that if procurement contracts are signed and implemented smoothly, it will help expand the sales range of the relevant products, enhance market share, and increase brand influence [1] - The company also cautioned that the procurement contracts have not yet been signed, and there is uncertainty regarding the subsequent progress and actual impact on the company [1]